Polymer Factory’s issue of units prior to listing significantly oversubscribed
On March 11, 2021, the subscription period in Polymer Factory Sweden AB’s (“Polymer Factory” or the “Company”) issue of units ended. The issue of units was subscribed to a total of approx. 687 percent (incl. pre-subscription). Through the issue of units, 1,704,198 shares and 586,066 warrants of series TO 1 are issued, providing Polymer Factory with initially approx. SEK 13 million (before issue costs of approx. SEK 1.28 million), of which approx. SEK 1.8 million pertains to bridge loan received in February 2021 and approx. SEK 0.37 million is attributable to compensation to bridge financiers. Settlement notes are expected to be sent out today, on March 16, 2021. Sedermera Fondkommission has acted as financial advisor in the issue of units.
Present CEO Michael Malkoch and incoming CEO Elin Mignérus comments:
“We are delighted to announce that our issue of units, prior to listing at Spotlight Stock Market, has been received with great interest from investors. Polymer Factory now has 973 new shareholders. We would like to thank everyone who has been involved in making this possible, especially our team and partners, as well as other interested parties who have chosen to invest in Polymer Factory. Through this successful capitalization, we will be in a good position to expand the business and sales organization and accelerate the company’s growth as we work diligently towards achieving our targets for the years ahead.”
Subscription and allocation
The issue of units was subscribed to approx. SEK 89 million (including subscription commitments), corresponding to a subscription rate of approximately 687 percent. A total of 1,704,198 shares and 568,066 warrants of series TO 1 are thus issued through the unit issue. Polymer Factory will initially receive initially approx. SEK 13 million (before issue costs of approximately SEK 1.28 million), including bridge loan and compensation to bridge financiers, amounting to approx. SEK 1.8 million and approx. SEK 0.37 million respectively.
Number of shares and share capital
Once the initial issue has been registered with the Swedish Companies Registration Office (Swe. Bolagsverket), the total number of shares in Polymer Factory will amount to 6,859,198 and the share capital will be SEK 685,919.80. In addition, there will be a total of 568,066 outstanding warrants of series TO 1.
Warrants of series TO 1
The exercise period of the warrants of series TO 1 is planned to take place between February 24, 2022 – March 17, 2022. Each warrant entitles the holder to subscribe for one new share in the Company at a price of SEK 9.10 per share. Upon full exercise of all attached warrants, the Company will receive approx. SEK 5.2 million before issue costs.
Listing at Spotlight Stock Market
Polymer Factory’s shares have been approved for listing at Spotlight Stock Market. The first day of trading is projected to be April 7, 2021. The share will be traded under the ticker name “POLYMER”, with ISIN code SE0015244470, and the warrant will be traded under the ticker “POLYMER TO 1”, with ISIN code SE0015557293.
Polymer Factory has in connection with the issue of units appointed Sedermera Fondkommission as financial advisor, Markets & Corporate Law Nordic AB as the legal advisor, and Nordic Issuing as issuing agent.
For additional information about the issue of units, please contact:
Phone: +46 (0) 40-615 14 10
For more information about Polymer Factory, please contact:
Michael Malkoch, CEO
Phone: +46 (0) 70 221 18 75
This information is information that Polymer Factory is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on March 16, 2021.
Polymer Factory is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.